PharmaCyte Biotech Inc (PMCB)

[concordia]

Eight years of claiming Clinical Trials Soon. Eight years of NOTHING.

Nuvilex, Inc. Readies Pancreatic Cancer Treatment for Expanded Phase II Clinical Trials


Jun 6, 2011 10:22am


SCOTTSDALE, Ariz.--(BUSINESS WIRE)-- Nuvilex, Inc. (OTCQB: NVLX) announced today it is aggressively engaging the steps necessary to use its encapsulated cell technology for pancreatic cancer in expanded Phase II clinical trials in the United States, Europe and Australia. The Company’s objective is to have a protocol submitted to the regulatory agencies in these countries as quickly as possible.

In conjunction with SG Austria, the world’s leading cell encapsulation technology company based in Singapore, Nuvilex has already activated our plan for rapid entry into expanded pancreatic cancer clinical trials. Necessary funding to initiate this phase of the study has been secured and the principals from both companies are working in close harmony to develop, implement, and oversee plans for the new clinical trials.